The Motley Fool

Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear

Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line. There are opportunities ahead for ...
USA Today

FDA reverses course, agrees to review Moderna's flu vaccine

The Food and Drug Administration reversed an earlier decision to not review Moderna's flu vaccine and will evaluate the company's modified application for a potential approval, Moderna said on Feb. 18 ...
The Conversation

FDA’s abrupt flip‑flop on Moderna’s mRNA flu shot highlights growing risks to drug‑makers of investing in vaccines

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...
Nasdaq

Why Moderna Stock Just Popped

The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind. The FDA had previously rejected Moderna's application, refusing even to ...
CBS News

Moderna says FDA will now review its new flu vaccine, reversing earlier decision

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...
NBC Chicago

Moderna says the FDA will consider its new flu shot after resolving a public dispute

The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of-its-kind shot.
CNN

FDA reverses course and will review Moderna’s mRNA flu shot, company says

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday. About two weeks ago, the FDA sent Moderna a ...
The New York Times

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology. By Christina Jewett and ...
The Washington Post

FDA reverses course and will review Moderna’s mRNA-based flu shot

The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, company and federal officials said ...
Wall Street Journal

Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls

Moderna MRNA3.60%increase; green up pointing triangle reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% revenue growth in 2026 following ...
The Conversation

FDA rejects Moderna’s mRNA flu vaccine application ‑ for reasons with no basis in the law

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...